PaulRPentelMD
Internal Medicine • Minneapolis, MNProfessor, Medicine, University of Minnesota Medical School, Minneapolis
Are you Dr. Pentel?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 41 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
701 Park Ave
Minneapolis, MN 55415Phone+1 612-873-2300Fax+1 612-904-4299- Is this information wrong?
Summary
- Dr. Paul Pentel, MD is a board certified internist in Minneapolis, Minnesota. He is currently licensed to practice medicine in Minnesota. He is affiliated with Hennepin Healthcare and is a Professor at University of Minnesota Medical School.
Education & Training
Hennepin HealthcareResidency, Internal Medicine, 1975 - 1979
Stanford University School of MedicineClass of 1975
Certifications & Licensure
MN State Medical License 1976 - 2024- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Effects of Dynorphin 1-13 on Heroin Addiction - 1 Start of enrollment: 1994 Aug 01
Publications & Presentations
PubMed
- 3 citationsPre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.Fatima A Hamid, Cheryl L Marker, Michael D Raleigh, Aaron Khaimraj, Scott Winston, Paul R Pentel, Marco Pravetoni> ;Vaccine. 2022 May 20
- 12 citationsPharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder.Michael D. Raleigh, S. J. King, Federico Baruffaldi, Amy Saykao, Fatima Hamid, S. Winston, Mark G. LeSage, Paul R. Pentel, Marco Pravetoni> ;Neuropharmacology. 2021 Jun 11
- 3 citationsThe reinforcement threshold and elasticity of demand for nicotine in an adolescent rat model of depression.John R. Smethells, Danielle Burroughs, Amy T. Saykao, Paul R. Pentel, Amir H. Rezvani, Mark G. LeSage> ;Drug and Alcohol Dependence. 2021 Feb 1
- Join now to see all
Press Mentions
To Fight Opioid Crisis, UW Researchers Take New Shot at Developing Vaccine Against Addictive DrugsJanuary 5th, 2022
Grant Support
- Preclinical Studies Of A Heroin/Morphine Vaccine For Opiate AddictionNational Institute On Drug Abuse2010–2011
- Multivalent Vaccine For Opiate AddictionNational Institute On Drug Abuse2008–2011
- Immunization To Block The Effects Of NicotineNational Institute On Drug Abuse2000–2011
- Project 2: Nicotine Exposure Reduction In RatsNational Institute On Drug Abuse2004–2008
- TSE Inhalation System: Tobacco &NicotineNational Center For Research Resources2005
- TSE Inhalation System: Tobacco &Bone HealingNational Center For Research Resources2005
- TSE Inhalation System: Lung CancerNational Center For Research Resources2005
- TSE Inhalation System: Adult Human Stem CellNational Center For Research Resources2005
- TSE Inhalation SystemNational Center For Research Resources2005
- Vaccine Effects On Fetal Nicotine Exposure In RatsNational Institute On Drug Abuse2002–2005
- Effects Of Nicotine Vaccine In RatsNational Institute On Drug Abuse2000–2002
- Immunization To Block The Central Effects Of NicotineNational Institute On Drug Abuse1997–1999
- Core--AnalyticNational Institute On Drug Abuse1997–1998
- Effects Of Dynorphin On Heroin AddictionNational Center For Research Resources1996–1997
- Effects Of Dynorphin 1-13 On Heroin AddictionNational Institute On Drug Abuse1993–1994
- Antibody Treatment Of Antidepressant ToxicityNational Institute Of Mental Health1992–1994
- Antibody Treatment Of Desipramine ToxicityNational Institute Of Mental Health1988–1990
- Antibody Treatment Of Desipramine ToxicityNational Institute Of Mental Health1986
Hospital Affiliations
Hennepin HealthcareMinneapolis, Minnesota
